Brussels (Belgium) - November 17, 2009 - Press Release - UCB
announced today its intention to make organizational changes in some
divisions at its sites in Braine-l'Alleud (Belgium) and Slough (UK).
The main purpose of this project is to optimize the transformation of
UCB into a biopharma leader with the ambition to realize sustainable
growth for the years to come.
Both Braine-l'Alleud and Slough are key strategic sites and play a
pivotal role in UCB's biopharma strategy. At both the Braine-l'Alleud
and Slough sites, UCB intends to adapt its NewMedicines division;
additionally on the Braine-l'Alleud site, the company intends to
streamline manufacturing support services, industrial development and
some administrative functions. In this way, UCB aims to broaden its
biotechnological capability in line with new product and pipeline
requirements. The project also takes into account the need to invest
in newly launched products while maintaining profitability following
UCB today informed its employees and employee representatives of the
proposed projects that could impact 174 positions in Braine-l'Alleud
and 44 positions in Slough and is subject to the information and
consultation procedures which apply in Belgium and the UK. In
parallel a series of new functions could also be created to meet new
biopharma profiles and allow UCB to pursue its transformation.
"UCB's ability to adapt is key to maintaining our competitiveness
within the world of biopharma innovation'' said Roch Doliveux, CEO of
UCB. "We will help our employees to go through the changes ahead of
us and I commit to an open and constructive dialogue with our social
partners. Our priority will be to look for solutions that lead to a
Pictures available for download at
For further information
Nancy Nackaerts, External Communications, UCB
T +32 (0)473.864.414, , email@example.com
Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, firstname.lastname@example.org
Cindy Maas, External Communications, UCB
T +32 (0)495.588.377, email@example.com
Encompassing discovery research activities through to proof of
concept, UCB NewMedicines(TM) is an innovative and externally
networked organisation established to secure the future pipeline and
deliver UCB's breakthrough products of the future.
A disseminated research organisation will maximise UCB's investment
in scientific and medical breakthroughs via a highly collaborative
approach to forming teams and projects to create new medicines. Based
on a 'hub' model of operation, UCB NewMedicines(TM) is located on two
key sites at Braine-l'Alleud, Belgium and Slough, UK. Operations at
these hubs focus on the therapeutic areas of CNS (Central Nervous
System) and Immunology with strong technology platforms underpinning
the research. The organisation houses leaders and experts who possess
the highest level skills to search, review, decide and transact on
all aspects of the portfolio in all functions.
Internal resources differentiate UCB whilst external resources are
accessed for routine activities or to provide specialist
complementary skills and capabilities. The organisation fully
embraces external networking to support our focus on the pipeline
delivery and breakthrough science. Medics and patients inform
choices from the outset of projects.
UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company
dedicated to the research, development and commercialization of
innovative medicines with a focus on the fields of central nervous
system and immunology disorders. Employing approximately 10 000
people in over 40 countries, UCB generated revenue of EUR 3.6 billion
in 2008. UCB is listed on Euronext Brussels (symbol: UCB).
Forward looking statement
This press release contains forward-looking statements based on
current plans, estimates and beliefs of management. Such statements
are subject to risks and uncertainties that may cause actual results
to be materially different from those that may be implied by such
forward-looking statements contained in this press release. Important
factors that could result in such differences include: changes in
general economic, business and competitive conditions, effects of
future judicial decisions, changes in regulation, exchange rate
fluctuations and hiring and retention of its employees.
For the pdf-version of this press release, please click on the link
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.